Novo and Pfizer are among the investors set to exit the cancer therapy developer, which has set a $100m target for its initial public offering.
Bolt Biotherapeutics, a US-based oncology therapy developer backed by property developer Nan Fung and pharmaceutical firms Pfizer and Novo, has filed to raise up to $100m in its initial public offering. Founded in 2015 as a Stanford University spinout, Bolt is developing antibody drug conjugates to treat cancer and will channel part of the IPO…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.